Health-related quality of life in HIV-1-infected patients on HAART: a five-years longitudinal analysis accounting for dropout in the APROCO-COPILOTE cohort (ANRS CO-8)

Qual Life Res. 2007 May;16(4):577-91. doi: 10.1007/s11136-006-9151-7. Epub 2007 Feb 1.

Abstract

Background: The long-term efficacy of Highly Active Antiretroviral Therapies (HAART) has enlightened the crucial role of health-related quality of life (HRQL) among HIV-infected patients. However, any analysis of such extensive longitudinal data necessitates a suitable handling of dropout which may correlate with patients' health status.

Methods: We analysed the HRQL evolution over 5 years for 1,000 patients initiating a protease inhibitor (PI)-containing therapy, using MOS SF-36 physical (PCS) and mental (MCS) scores. In parallel with a classical separate random effects model, we used a joint parameter-dependent selection model to account for non-ignorable dropout.

Results: HRQL evolved according to a two-phase pattern, characterized by an initial improvement during the year following HAART initiation and a relative stabilization thereafter. Immunodepression and self-reported side effects were found to be negative predictors of both PCS and MCS scores. Hepatitis C virus coinfection and AIDS clinical stage were found to affect physical HRQL. Results were not significantly altered when accounting for dropout.

Conclusion: Such results, obtained on a large sample of HIV-infected patients with extensive follow-up, underline the need for a regular monitoring of patients' immunological status and for a better management of their experience with hepatitis C and HAART.

Publication types

  • Multicenter Study

MeSH terms

  • Adult
  • Antiretroviral Therapy, Highly Active*
  • Female
  • France
  • HIV Infections / complications
  • HIV Infections / drug therapy*
  • HIV Infections / metabolism
  • HIV-1 / drug effects*
  • HIV-1 / enzymology
  • Health Status
  • Hepatitis C / complications
  • Humans
  • Longitudinal Studies
  • Male
  • Models, Statistical
  • Outcome Assessment, Health Care / statistics & numerical data*
  • Patient Dropouts
  • Prospective Studies
  • Protease Inhibitors / pharmacology
  • Protease Inhibitors / therapeutic use
  • Quality of Life*
  • Sickness Impact Profile*
  • Time Factors
  • Treatment Outcome*

Substances

  • Protease Inhibitors